Novel treatment options for epilepsy

Focus on perampanel

V. Franco, F. Crema, A. Iudice, G. Zaccara, E. Grillo

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Perampanel is a new chemical entity recently approved in the United States (US) and European Union (EU) as adjunctive treatment of partial-onset seizures with and without secondary generalization in patients with epilepsy aged 12 years and older. Pharmacological studies suggest that perampanel acts with a new mechanism of action via non-competitive antagonism of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor of glutamate, the main mediator of excitatory neurotransmission in the central nervous system. Perampanel is completely absorbed after oral administration. The drug is 95% bound to plasma proteins and is extensively metabolized by oxidation followed by glucuronidation. Perampanel has an elimination half-life of approximately 52-129 h, allowing once daily dosing, with peak plasma levels observed 0.25-2 h post-dose. Randomized placebo-controlled trials of adjunctive treatment have demonstrated that once-daily perampanel doses of 4-12 mg/day significantly reduced partial-onset seizure frequency in patients with pharmacoresistant epilepsy along with a favorable tolerability profile. In perampanel pivotal trials, the most frequently reported treatment emergent adverse events (>10%) included dizziness, somnolence, fatigue and headache. Perampanel therapeutic response was maintained in patients included in the long term open-label extension studies for up to 4 years. Based on these data, perampanel offers a valuable option in the add-on treatment of partial-onset and secondarily generalized seizures.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalPharmacological Research
Volume70
Issue number1
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Epilepsy
Seizures
Therapeutics
AMPA Receptors
perampanel
Dizziness
European Union
Synaptic Transmission
Fatigue
Headache
Oral Administration
Half-Life
Blood Proteins
Glutamic Acid
Central Nervous System
Randomized Controlled Trials
Placebos
Pharmacology
Acids
Pharmaceutical Preparations

Keywords

  • AMPA receptors
  • Epilepsy
  • Glutamate
  • Mechanism of action
  • Perampanel

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel treatment options for epilepsy : Focus on perampanel. / Franco, V.; Crema, F.; Iudice, A.; Zaccara, G.; Grillo, E.

In: Pharmacological Research, Vol. 70, No. 1, 04.2013, p. 35-40.

Research output: Contribution to journalArticle

Franco, V. ; Crema, F. ; Iudice, A. ; Zaccara, G. ; Grillo, E. / Novel treatment options for epilepsy : Focus on perampanel. In: Pharmacological Research. 2013 ; Vol. 70, No. 1. pp. 35-40.
@article{a46c651934f34957856db38aaa571368,
title = "Novel treatment options for epilepsy: Focus on perampanel",
abstract = "Perampanel is a new chemical entity recently approved in the United States (US) and European Union (EU) as adjunctive treatment of partial-onset seizures with and without secondary generalization in patients with epilepsy aged 12 years and older. Pharmacological studies suggest that perampanel acts with a new mechanism of action via non-competitive antagonism of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor of glutamate, the main mediator of excitatory neurotransmission in the central nervous system. Perampanel is completely absorbed after oral administration. The drug is 95{\%} bound to plasma proteins and is extensively metabolized by oxidation followed by glucuronidation. Perampanel has an elimination half-life of approximately 52-129 h, allowing once daily dosing, with peak plasma levels observed 0.25-2 h post-dose. Randomized placebo-controlled trials of adjunctive treatment have demonstrated that once-daily perampanel doses of 4-12 mg/day significantly reduced partial-onset seizure frequency in patients with pharmacoresistant epilepsy along with a favorable tolerability profile. In perampanel pivotal trials, the most frequently reported treatment emergent adverse events (>10{\%}) included dizziness, somnolence, fatigue and headache. Perampanel therapeutic response was maintained in patients included in the long term open-label extension studies for up to 4 years. Based on these data, perampanel offers a valuable option in the add-on treatment of partial-onset and secondarily generalized seizures.",
keywords = "AMPA receptors, Epilepsy, Glutamate, Mechanism of action, Perampanel",
author = "V. Franco and F. Crema and A. Iudice and G. Zaccara and E. Grillo",
year = "2013",
month = "4",
doi = "10.1016/j.phrs.2012.12.006",
language = "English",
volume = "70",
pages = "35--40",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "1",

}

TY - JOUR

T1 - Novel treatment options for epilepsy

T2 - Focus on perampanel

AU - Franco, V.

AU - Crema, F.

AU - Iudice, A.

AU - Zaccara, G.

AU - Grillo, E.

PY - 2013/4

Y1 - 2013/4

N2 - Perampanel is a new chemical entity recently approved in the United States (US) and European Union (EU) as adjunctive treatment of partial-onset seizures with and without secondary generalization in patients with epilepsy aged 12 years and older. Pharmacological studies suggest that perampanel acts with a new mechanism of action via non-competitive antagonism of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor of glutamate, the main mediator of excitatory neurotransmission in the central nervous system. Perampanel is completely absorbed after oral administration. The drug is 95% bound to plasma proteins and is extensively metabolized by oxidation followed by glucuronidation. Perampanel has an elimination half-life of approximately 52-129 h, allowing once daily dosing, with peak plasma levels observed 0.25-2 h post-dose. Randomized placebo-controlled trials of adjunctive treatment have demonstrated that once-daily perampanel doses of 4-12 mg/day significantly reduced partial-onset seizure frequency in patients with pharmacoresistant epilepsy along with a favorable tolerability profile. In perampanel pivotal trials, the most frequently reported treatment emergent adverse events (>10%) included dizziness, somnolence, fatigue and headache. Perampanel therapeutic response was maintained in patients included in the long term open-label extension studies for up to 4 years. Based on these data, perampanel offers a valuable option in the add-on treatment of partial-onset and secondarily generalized seizures.

AB - Perampanel is a new chemical entity recently approved in the United States (US) and European Union (EU) as adjunctive treatment of partial-onset seizures with and without secondary generalization in patients with epilepsy aged 12 years and older. Pharmacological studies suggest that perampanel acts with a new mechanism of action via non-competitive antagonism of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor of glutamate, the main mediator of excitatory neurotransmission in the central nervous system. Perampanel is completely absorbed after oral administration. The drug is 95% bound to plasma proteins and is extensively metabolized by oxidation followed by glucuronidation. Perampanel has an elimination half-life of approximately 52-129 h, allowing once daily dosing, with peak plasma levels observed 0.25-2 h post-dose. Randomized placebo-controlled trials of adjunctive treatment have demonstrated that once-daily perampanel doses of 4-12 mg/day significantly reduced partial-onset seizure frequency in patients with pharmacoresistant epilepsy along with a favorable tolerability profile. In perampanel pivotal trials, the most frequently reported treatment emergent adverse events (>10%) included dizziness, somnolence, fatigue and headache. Perampanel therapeutic response was maintained in patients included in the long term open-label extension studies for up to 4 years. Based on these data, perampanel offers a valuable option in the add-on treatment of partial-onset and secondarily generalized seizures.

KW - AMPA receptors

KW - Epilepsy

KW - Glutamate

KW - Mechanism of action

KW - Perampanel

UR - http://www.scopus.com/inward/record.url?scp=84875201902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875201902&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2012.12.006

DO - 10.1016/j.phrs.2012.12.006

M3 - Article

VL - 70

SP - 35

EP - 40

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -